C-IJKGDeciduous Therapeutics
senescent cell clearance, immune surveillance activation
clearingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IJKG
C-IJKGC-IJKGsenescent cell clearance, immune surveillance activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Deciduous Therapeutics states that improving human health span can be achieved by developing medicines that activate the body’s own immune mechanism for eliminating senescent cells. The company presents senescent cells as a key driver of age-related disease and argues that when immune surveillance fails, these cells accumulate, create inflammation, and remodel surrounding tissue in harmful ways.
SourceDeciduous Therapeutics states that improving human health span requires developing medicines that activate the body’s own immune surveillance to eliminate senescent cells. The company presents senescent cells as a key driver of many age-related diseases because they accumulate when immune surveillance fails, create inflammation, and promote extracellular matrix remodeling that leads to metabolic and fibrotic harm. It further states that selectively removing these cells can dramatically improve disease pathology across age-related conditions.
SourceDeciduous Therapeutics states that improving human health span requires novel medicines that activate the body’s own immune mechanism to eliminate senescent cells. The company presents senescent cells as a key driver of many age-related diseases, arguing that when immune surveillance fails these damaged cells accumulate, create inflammatory signals, remodel surrounding tissue, and harm local environments.
Source